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I. Abstract 
Objectives: The main objective of this study was to characterise women who presented at 
Chris Hani Baragwanath Academic Hospital (CHBAH) between 12 and 20 weeks for 
termination of pregnancy (TOP). Secondary objectives were to determine time to abortion, 
compare sonar gestational age to gestational age by dates and reasons for late presentation. 
Method: This was a prospective cohort study of women over the age of 18 who were referred 
to CHBAH for second trimester TOP between August 2012 and May 2013. The exclusion 
criteria were pregnancies more advanced than 20 weeks gestation. Data was collected from 
the medical file and by interview. Demographics and reasons to terminate were extracted 
from the files. Outcome variables included bleeding, pain, and time to abortion. 
Results: One hundred and ninety one women (91.39%) aborted. The median age of women 
was 25.00 (IQR=21.00-31.00), range (18-43). Women older than 25 years were 33% less 
likely to abort than women less than 25 years of age. Ninety nine women (47.14%) bled 
severely. One woman had a uterine perforation following evacuation of the uterus. The 
median gestational age by sonar was14.71 (IQR=13.86-16.14), range (13.00-20.00). The 
median gestational age by dates was13.57 (IQR=12.29-15.00), range (4.14-26.28). One 
hundred and thirty five women (63.98%) had an MVA for RPOC using analgesia following 
medical induction. Two women (0.95%) needed hysterotomy following failed TOP.  The 
median time to abortion was 11.50(IQR=8.67-17.92), range (3.50-69.33) and incidence rate 
of 0.5 per hour or 1 per 2hours. 
Conclusion: The majority of women (91%) aborted within 72 hours following medical 
induction with less complication rate and short induction to abortion time. This affirm 
misoprostol efficacy as the suitable drug for conducting second trimester medical TOP.  
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CHAPTER 1: INTRODUCTION 
This chapter gives an overview on abortion and its prevalence in various regions of the world 
and is followed by the problem statement and justification of the study.  
1.1. Introduction 
Abortion of an unwanted pregnancy is one of the most common gynaecological procedures 
performed annually. Globally, it is estimated that 29 Termination of Pregnancy’s (TOP) are 
performed per 1000 women aged 15- 44 years every year. Legal TOP’s are usually safe in 
well-resourced countries (1). For every 100 000 procedures performed, the combined rate of 
mortality is 10 women (2). Countries which are poorly resourced and with stringent abortion 
laws have  an unsafe abortion rate estimated at 98%(3)  and approximately 130 women die 
from complications related to unsafe abortions daily (4). 
Maternal death due to termination of unwanted pregnancy increases with a more advanced 
gestational age. The Centres for Disease Control and Prevention (CDC) indicated that 
maternal death associated with termination of unwanted pregnancy ranges from 0.5/100 000  
gestation less  than 9 weeks to 2.9 at gestation between 13 and 15 weeks , 9.3 at gestation 
between 16 and 20 weeks, and 12.0 at more than 20 weeks gestation(5).  
“Worldwide, approximately 10% of abortions take place in the second trimester”, but 
developing or low resource  countries like South Africa (SA) and India have high figures of 
up to 25% to 30 % ( 6). In SA, with the passing of the Choice of Termination of Pregnancy 
Act no.92 of 1996 (CTOP), safe pregnancy terminations are available for the majority of 
women (7, 8).  About 1600 abortions per year were reported in 1996 before the passing of the 
Act. This number went up to 26 519 in 1997 and jumped to nearly 90 000 in 2004. The 
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reason for the significant difference in the numbers before and after the Act may be because 
most abortions were performed illegally before the Act was passed and therefore not reported 
(9). 
Abortion in SA is still associated with a number of problems; the number of facilities that 
perform them have reduced (10), women present late for abortions, contraceptive services are 
lacking, repeat abortions are common, women do not access safe TOP because of stigma and 
there are no services in some parts of the country. Second trimester abortions are associated 
with more complications and a greater cost (11). 
 At CHBAH 1224 second trimester abortions were performed in 2010 and 807 were 
performed in 2011 (12). The main objective of this study is therefore to explore factors 
associated with late presentation, reasons for late presentation and complications associated 
with second trimester TOP.   
1.2. Problem statement 
Abortion in the second trimester makes up 10-15% of the overall abortions worldwide and 
the majority (more than half) are considered unsafe (13). Generally, TOP is safe in developed 
countries with more abortion resources but mid - trimester abortion still accounts for higher 
mortality than TOP performed in the first trimester irrespective of the level of country’s 
development. The dangers of mortality rise with increase in gestational age (14). 
CHBAH is designated to conduct second trimester abortions and deal with complications 
associated with abortion such as haemorrhage, uterine rupture, sepsis, cervical laceration, 
uterine atony, perforation, retained tissue, and coagulopathy (15).  
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A local retrospective study which was not published conducted by Gamedze et al looking at 
second trimester abortions at CHBAH showed that the number of failed TOPs and the need 
for surgical intervention is high. This is a concern and there is a need to investigate why 
women present late for pregnancy terminations. 
1.3. Justification 
Ideally women who are not planning pregnancy should be using contraception. If 
contraception fails they must seek termination of pregnancy as early as possible. Knowing the 
reasons why women present late for abortions may aid in tailoring services for safe abortions 
and may also assist with informing education programs for women.  
By investigating why women present late, we may be able to provide information to women 
and health care workers on how to reduce late presentation for TOP. Reducing second 
trimester abortions may help reduce complications such as haemorrhages, infection, uterine 
rupture, perforation and maternal death. Knowing the time to abortion may assist with 
logistical aspects of TOP services. 
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CHAPTER 2: LITERATURE REVIEW 
This chapter defines abortion and describes why safe abortion is an imperative for public 
health. Reasons for abortion and in particular second trimester abortion will be explored. 
Methods of procuring abortion and complications associated with abortion will then be 
described and will be followed by the aim and objectives of the study. 
2.1. Definition and background 
Abortion occurs when an unwanted pregnancy is terminated by use of any method before 
viability is reached by the foetus. Gestational age of 23-24 weeks is currently the cut off for 
viability (16). “Second trimester or mid-trimester is a period ranging from 13 to 28 weeks of 
gestation which again is subdivided into an early period between 13 and 20 weeks and a late 
period between 20 and 28weeks”(17). 
TOP is associated with minimal complications when it is done in a medical centre with 
required resources or equipment and in countries with no restrictive laws. “Of the 210 million 
pregnancies that occur each year, over 46 million (22%) end in induced abortions, mostly 
during the first trimester (18)”.  Mid-trimester abortions represent between 10% and 15% of 
all induced abortions but result in two-thirds of all serious complications (19).  
One of the main challenges with managing mid-trimester TOP is the development of safe and 
effective procedures or techniques. Recently, the management of mid-trimester abortion is 
mostly by medical induction; operative management is also effective and should be used but 
can result in serious complications (20). Unsafe abortions are responsible for up to 13% of 
maternal deaths globally, estimated at 47 000 mortalities per year (21). United States of 
America (USA) has 0.7 maternal mortalities per 100 000 procedures (22). Developing 
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countries with few resources have case fatality rate’s (CFR) as high as 218 per 100 000 
unsafe abortions (23). It will be difficult for many developing or low income countries to 
meet the millennium development goal number five, that is to reduce maternal death by 2015 
by 75% if they fail to address avoidable factors leading to maternal mortality from unsafe 
abortions (24). 
The CTOP Act No. 92 of 1996 regulates abortion in SA. The passing of the CTOP Act in SA 
resulted in a significant decline in maternal mortality and the incidence of women presenting 
with incomplete abortions. Despite a significant decline in the CFR, mortality index (MI) and 
maternal mortality rate (MMR), the presentation of critically ill women has not changed. The 
MMR per 100 000 births from abortion was 63.6 in 1997 to1998 and dropped to 5.54 per 100 
000 births in 2003 to 2005 (25). 
 The Act allows abortion on demand up to 12 weeks and may be performed by a doctor or an 
appropriately trained nurse or midwife. Because of possible complications of second 
trimester abortion, the law is more stringent for pregnancies above 12 weeks (13 to 20 weeks) 
and states that “from the 13th up to and including the 20th week of the gestation period, if a 
medical practitioner, after consultation with the pregnant woman is of the opinion that 
 The continued pregnancy would pose a risk to the woman’s physical or mental health 
 There exist a substantial risk that the fetus would suffer from a severe physical or 
mental abnormality; or 
 The pregnancy resulted from rape or incest; or 
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 The continued pregnancy would significantly affect the social or economic 
circumstances of the woman” 
And for pregnancies more than 20 weeks gestation “After 20th week of gestation period if a 
medical practitioner, after consultation with another medical practitioner or a registered 
midwife is of the opinion that the continued pregnancy 
 Would endanger the woman’s life 
 Would results in a severe malformation of the foetus; or 
 Would pose a risk of injury to the foetus” 
A second trimester abortion can only be performed by a doctor (26). The Choice on 
Termination of Pregnancy Amendment ACT no. 38 of 2004 made an addition of a registered 
nurse in the termination of pregnancy on request during the first 12 weeks of pregnancy (27). 
2.2. Indications and reasons for second trimester abortion 
Medical and social factors may contribute to decision making regarding termination and may 
lead to a delay in seeking TOP. Other factors that may lead to delays are late pregnancy 
testing and diagnosis, financial barriers and delay within the referral system (28).  
  Abortion because of fetal anomalies also contributes to the increase in second trimester 
abortion as anomaly scans are best done in the second trimester. Late detection of genetic 
anomalies results in a delay in TOP in 47%-48% of women.  (29). 
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 Other reasons for mid-trimester TOP include foetal death, pre-eclampsia and prelabour 
preterm rupture of membrane (30).  
2.3. Methods of procuring an abortion 
There are several methods of performing an abortion; surgical, medical and mixed methods. 
Surgical abortion techniques in the form of D&E are widely used in many regions around the 
world especially in the United States of America where more than 98% of second trimester 
TOP were performed by using D&E (31). . 
2.4. Cervical priming 
Cervical pre-operative preparation is important in order to achieve dilation and softening 
prior to a surgical procedure resulting in minimal uterine and cervical trauma. It is 
recommended for most second trimester TOPs except when a hysterotomy is indicated. The 
cervix needs to be primed to permit instruments and retained products of conception (RPOC) 
without inflicting injury to the cervix. The cervical dilation needed for D&E rises with 
gestational age. Late TOPs require additional force to effectively dilate the cervix and this 
has the potential risk of damaging the cervix and causing other complications (32).  Below 
are the common cervical priming and induction agents: 
2.4.1. Laminaria 
Laminaria is made from laminaria japonica and laminaria digitata seaweed stems, which are 
harvested, dried and made into cervical tents. Tents are from 2 -10mm in diameter and 60 - 
85mm in length. When placed, they swell or bulge up to 4 times their original diameter 
following fluid absorption from the cervix, for example, a 3mm laminaria tent will achieve up 
to 1cm dilatation in situ overnight (33). The majority of cervical ripening usually happens in 
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the initial 6 hours. The cervical dilation puts pressure on the cervical canal which leads to 
prostaglandin (PG) production and this will allow manual dilation to be easy (34).  
2.4.2. Lamicel 
Lamicel is a synthetic osmotic dilator that was first reported in 1982. It is a dehydrated 
polyvinyl alcohol sponge embedded with 450mg of magnesium sulphate. It works faster than 
laminaria with cervical ripening effects occurring within 2 hours to 6 hours (35). It is usually 
67mm in length and can bulge to 3 - 4mm its original state. It basically does not produce 
radial force in view of the fact that it is compressible (36). It may work by stimulating PG 
production or breaking down collagen tissues within the cervix. The exact mechanism is 
unclear (37). 
2.4.3.   Dilapan S 
Dilapan S is made up of aquacryl which is the polyacrylate associated proprietary hydrogel 
and is a synthetic osmotic dilator. When dry, it exists in length of 55 and 65mm with the 
diameters of 3 - 4mm. In situ, Dilapan S swells 3 - 4times in diameter. When using a 4mm 
dilator, major effects are seen within 2 hours and it produces 7.8 - 10mm of cervical dilation.  
Dilapan S needs longer tents for cervical dilation and shortens by 18% as it bulges. It 
archives sufficient cervical dilation in the shortest time frame (38). 
2.4.4. Misoprostol 
Misoprostol is a synthetic PGE1 analogue (15-deoxy-16hydroxy-16methyl PGE1). It was 
developed for the management of peptic ulcer and it was later used off-label as an 
abortifacient. “It is cheap, stable at room temperature and can be stored for a long time.  
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Misoprostol in the required dose has few minor side effects and it is easily accessible in many 
centres” (39). 
Misoprostol is efficient when taken orally and is metabolised by the liver. It has a half-life of 
up to 40 minutes following a plasma concentration peak at 30 minutes after oral 
administration (40). 
 Studies have looked at Misoprostol as an alternative cervical priming agent to natural 
osmotic dilators like Dilapan S, Laminaria and Lamicel. Like Lamicel, Misoprostol makes 
the cervix soft rather than expanding it (41). 
2.5. Second trimester abortion procedures 
2.5.1. Medical abortion 
I.  Intra amniotic instillation 
Intra-amniotic solution is given via amniocentesis, using concentrated saline or urea. This 
technique was most frequently used in the 1970s and 1980s. It has been substituted by newer 
methods because of safety concerns, increased duration from induction to attaining abortion 
and incidences of retained placenta or RPOC which necessitate curettage following fetal 
expulsion (42).  
II.  Intra-amniotic PG 
Intra-amniotic PG has complications like major blood loss that requires blood transfusion. 
Despite all these, intra-amniotic PG administration remains a successful method of mid-
trimester TOP. In a Czech study performed between January 1991 and June 1997 that 
included 179 women, pregnancies were terminated using intra-amniotic PG. Of the 179 
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women, 72% of them aborted within 24 hours.  Intra-amniotic administration was repeated 
twice in 26% of women and three times in 2% of women. The mean induction period was 
22.6 hours (43). The World Health Organisation (WHO) PG task force organized a study 
where both the PGF2α and hypertonic saline were found to be more efficient in mid- 
trimester TOP. PGF2α was more efficacious with significantly higher rates in the initial 48 
hours (44). 
III. Oxytocin 
This is a potent uterotonic hormone synthesized physiologically by the posterior section of 
the pituitary gland. Synthetic Oxytocin is mainly used in second trimester TOP as an add-on 
to either other induction drug agents or mechanical dilators. If intravenous (IV) Oxytocin is 
used in isolation as an induction agent, much higher dosages are needed than in full-term 
induction of labour, not forgetting that in early gestation, there is failure to respond by 
myometrial oxytocin receptors of the uterus. IV Oxytocin increases the frequency of 
contraction, amplitude and uterine basal tone. A common high dose side effect is fluid 
overload, which can be prevented by giving intermittent dosages. 
The use of oxytocin at a higher dosage together with mechanical techniques is not a 
preferable  method of abortion and is rarely a method of choice due to lack of response of the 
uterus to Oxytocin at this level of gestation. (45). 
IV. Oxytocin and PG preparation 
A randomised control trial (RCT) compared the efficiency of a high vaginally administered 
Misoprostol regimen to concentrated intravenous infusion (IVI) of Oxytocin in combination 
with low dose vaginally administered Misoprostol for second trimester labour induction. The 
two modalities were compared in terms of induction to delivery time and adverse effects. It 
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was noted that high dose Misoprostol greatly shortened mid-trimester induction to abortion 
time and the success rate of induction is shortened to within 12hours. Using high dose 
Oxytocin in combination with low dose vaginal Misoprostol failed to produce expected 
combined benefit (46). 
V.  Prostaglandins 
The introduction of PGs and their analogues has been shown to be a more efficient and a 
safer method of medical TOP in the mid-trimester. RCT have reported shorter duration of 
time from induction of labour to aborting the fetus when Misoprostol is used (47). 
VI. The use of Misoprostol alone for second trimester abortion 
Studies show that Misoprostol used alone for mid- trimester TOP is effective. The only 
disadvantage is its longer time from induction to abortion, side effects are more common and 
high doses are needed compared to Misoprostol plus Mifepristone regimen. Mifepristone is a 
more expensive induction agent and is not readily available in many centres, even in some 
regions in the USA. Misoprostol on its own should be used in regions that do not have or 
cannot afford Mifepristone (48). 
 Many studies have documented the success rate, regimens and routes of administrating 
Misoprostol on its own in the mid- trimester TOP.  Dosages from as low as 200microgram 
(µg) to 800µg at intervals of between 3 and 12 hours have been used by researchers.  Higher 
doses of 600µg and 800 µg have produced successful abortion rates, but have higher 
incidences of complications like vomiting, diarrhoea, nausea and fever. The 6 hour dose 
interval is less effective than the 3 hour dose interval (48). 
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Meckstroth et al compared Misoprostol administered buccaly, rectally and vaginally. Vaginal 
Misoprostol was also compared when it was administered dried and when it was moistened  
and found that Misoprostol administered buccaly has lower serum drug levels compared to 
vaginal Misoprostol even though uterine contractility and tone were increased when all routes 
were compared. The rectal route of Misoprostol administration had both serum levels and 
uterine tone at the lowest level. Misoprostol administered vaginally has been shown to be the 
most efficacious method to carry out TOP effectively in the mid-trimester abortion with 
minimal adverse effects (49). The safety and efficiency of both oral and vaginal Misoprostol 
were compared and similarities were confirmed between the two routes (50). 
VII. Induction with Mifepristone and Misoprostol regimens 
The use of PGE1 analogues and Mifepristone to terminate pregnancy in the mid- trimester 
has been approved and recommended by international organizations like the Royal College of 
Obstetricians and Gynaecologists (RCOG) and WHO. The use of Mifepristone before 
Misoprostol as a combination results in safer and quicker abortion, especially in the mid-
trimester (51). 
Misoprostol and Mifepristone are more efficient when the initial Mifepristone dose is given 
and followed by Misoprostol 36-38hours later. A RCT of Misoprostol (vaginally) given 
together with Mifepristone versus after 36 - 38hours found that 91.5% aborted in the 
simultaneous group vs 100% in the misoprostol 36-38 hours later at 24hours period. There 
was a lower mean induction to abortion time of 4.9 hours in 36 - 38 hours compared to 10 
hours in the immediate group (52). 
Mifepristone use produces a 5-fold rise in sensitivity to PG 24 -48 hours following its 
administration (53). The synergy between Mifepristone and PG allows good success rate of 
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PG at lower dosages, with lower adverse effects. Mifepristone followed by PG for induction  
in the mid-trimester require approximately half the time as inductions using PG alone and 
approximately 95% women abort within 24hours(54). 
The RCOG recommendation for TOP in the second trimester using Misoprostol in 
combination with Mifepristone is to give Mifepristone 200mg followed by Misoprostol 
800µg vaginally36 - 48 hours later. Misoprostol (400 µg) is repeated 3 hours later and every 
3 hours until abortion occur for a total of 4 doses (55). 
2.5.2. Surgical abortion 
The surgical technique for mid- trimester abortion has evolved remarkably in the USA since 
the legalization of abortion in 1973. D&E was found to be safer and therefore more popular 
than labour induction during the early 1980s (56). At the moment, several surgical techniques 
for second trimester abortion are available and “these procedures are suction dilation and 
curettage (D&C), D&E, intact dilation and extraction(ID&E) and hysterotomy” (57).  
I.  Suction D&E 
This surgical procedure is only used during the early mid- trimester and should be avoided 
after 16 -18 weeks of gestation because fetal bones are already calcified which will make the 
task of fitting the products of conception through the suction tubing or cannula difficult. The 
average size of the tubing is mostly 12mm and the largest is 16mm in diameter. Cervical 
preparation includes using or putting osmotic dilators or using Misoprostol to dilate the 
cervix. (57). 
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II. Dilation and evacuation 
The efficacy and safety of D&E was documented through a series of studies (58).  D&E is 
currently conducted as a two stage procedure involving cervical dilation by using one or more 
sets of hygroscopic dilators or with Misoprostol alone for the cervical preparation. The 
second stage involves aspiration of amniotic fluid and trans-cervical evacuation using forceps 
6 – 24 hours following the first stage.  (59). Fourteen to nineteen millimetres is the baseline 
dilation needed to allow the majority of the instruments used to carry out  D&E, however, 
wider dilations are often required in advanced gestations to remove products of conception  
(60). 
Todd et al reported sufficient dilation following cervical preparation using 600µg of buccal 
Misoprostol in 32 women at 14 -16 weeks 2 - 4 hours prior D&E. “The procedure time was 
comparable with women at 16-18 weeks of gestation who had cervical ripening with 
Laminaria” (61). 
 Edelman et al conducted a study in order to ascertain if adjuvant Misoprostol given buccaly 
improves cervical ripening with Laminaria. The trial compared pre-operative cervical 
priming with Laminaria tent inserted overnight and either placebo or Misoprostol buccaly 90 
minutes prior mid-trimester D&E at 16-20 weeks gestation. “The study found no objective 
differences in cervical dilation measured by passage of rigid dilators, and there was no need 
for additional dilation or duration of procedure at less than 19 weeks”. Some surgeons 
subjectively documented easier dilation after pre-treatment with Misoprostol. Of note was 
that women who received buccal Misoprostol experienced more side effects. Researchers 
concluded that Misoprostol causes dilation of the cervix when used as a replacement to 
Laminaria in gestation beyond 19weeks (62). 
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Disadvantages of D&E are that clinicians are fully involved during the whole procedure and 
must cope with the site of removing the remains of the mid-trimester foetus in an intimate, 
direct and a more physical way which is a psychologically and emotionally traumatic 
experience (63). The advantage for both the provider and the patient is that the procedure can 
be scheduled on an outpatient basis and operation times are shorter compared to medical 
abortion which requires hospitalisation (64). 
III. Intact dilation and extraction 
 ID&E is almost the same as D&E and entails more than one placement of hygroscopic 
dilators over a 2-3days period to ensure more dilation of the cervix .This will lead to the 
removal of intact foetus except that the calvarium is decompressed (65).The RCOG 
description of the procedure includes all 4 elements as follows: 
 “Deliberate dilation of the cervix, usually over a sequence of days, 
 Instrumental conversion of the foetus to footling breech. 
 Breech extraction of the body. 
 Partial evacuation of the intracranial contents of the living foetus to effect vaginal 
delivery of a dead but otherwise intact foetus” (66). 
Intact dilation and extraction is vital in circumstances where anatomical preservation and 
conservation of the foetus is crucial (66). There are no good comparative studies to compare 
the efficiency and safety of D&E or ID&E but both are important useful procedures for 
offering safe second trimester abortion care  (67). 
28 
 
IV. Hysterotomy 
Hysterotomy was a most used procedure before the widespread use of D&E but is now 
seldom used. It is made up of laparotomy followed by the extraction of RPOC through 
hysterotomy incision and the procedure is completed when the uterus and abdomen are 
repaired. The procedure is the same as performing the caesarean section delivery on a pre-
term uterus .This procedure is performed in circumstances where the cervix is blocked by 
either uterine pathologies like fibroid or where the uterine cavity is so thin that manipulation 
of the instrument is impossible (68).  
In a retrospective study conducted at Charlotte Maxeke Johannesburg Academic Hospital 
(CMJAH), which looked at ways to actively manage mid-trimester TOP following failed 
medical induction, the incidence of hysterotomy was 0.5% among women who had failed a 
medical induction. The need for hysterotomy was influenced by presentation at advanced 
gestation (close to 20 weeks) and the presence of more than one caesarean deliveries or 
request by the woman for tubal ligation (69). There were no hysterotomies in women 
undergoing TOP who had had more than one previous caesarean delivery undergoing 
abortion in a study in the same institution by Daponte, Nzewanga and Guidozzi (70). 
2.6. Complications 
The prevalence of abortion related mortality rises with each week of gestation. The mortality 
rate was estimated at 0.1 for every 100 000 procedures at 8 weeks gestation or less and 8.9 
for every 100 000 procedures at 21 weeks or greater (71). Complications include 
disseminated intravascular coagulation (DIC), RPOC, embolism, tear of the cervix, 
infections, rupture of the uterus, haemorrhage, failed induction and Asherman’s syndrome 
(72). Complications can be grouped into immediate, delayed and late complications. 
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2.6.1. Immediate complications 
I.  Post abortion haemorrhage 
Post abortion haemorrhage was defined by the Family Planning society as haemorrhage that 
warrants blood transfusion, requires admission or has a blood loss of 500mls.  (73). D&E 
procedures require blood transfusion following haemorrhage in 0.1-0.6% of cases compared 
to 0.7% of abortions perfomed medically (74). Causes include RPOC, cervical laceration, 
abnormal placentation, DIC, uterine atony, uterine perforation and rupture. In one study of 
post abortion embolisation of the uterine artery for bleeding, the causes of bleeding were 
noted to be; uterine atony (52%), abnormal placentation (17%), cervical laceration (12%), 
uterine perforation (7%), lower uterine segment bleeding without atony (5%) and DIC (5%) 
(75). 
II. Retained products of conception  
RPOC or incomplete TOP has been higher with medical abortions (8%) than with D&E 
(<1%) (76). In some studies, incomplete TOP were more common following TOP with 
Misoprostol induction in the mid- trimester as compared to D&E (77). 
III. Uterine atony 
Uterine atony is a failure of uterus to contract and results in excessive bleeding .In a review 
of up to 3000 D&E cases, atony occurred in about 2.6% of women. Predictors of uterine 
atony were increased maternal age and gestational age (78). 
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IV.  Cervical laceration 
Cervical laceration has been noted following medical TOP and D&E and made up 3.3% of 
mid-trimester TOP cases (79). 
V. Uterine perforation 
The prevalence of perforation of the uterus in mid-trimester operative TOP is low, at 0.2 - 
0.5%. It usually occurs in combination with increased gestational age, lack of experience by 
the person conducting TOP and higher parity. They seldom occur in situations where the 
cervix is sufficiently prepared (80). 
VI. Uterine rupture 
Despite reported rupture of the uterus associated with medical abortions among women with 
previous caesarean scars and women without, the dangers of uterine rupture remain unknown. 
The danger of rupture of the uterus was 0.28% in women in women with previous caesarean 
delivery whereas it was 0.04% in women without a scar in studies reviewing mid-trimester 
TOP using Misoprostol (81). 
VII. Disseminated intravascular coagulation 
DIC arises as result of severe haemorrhage which may result in coagulopathy. The demise of 
the foetus in the mid-trimester put’s a woman at risk of developing DIC (82). 
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2.6.2. Delayed complications 
I. Infection 
The occurrence or incidence of post abortion infection in mid-trimester has not been clearly 
defined but figures ranging between 0.1- 4% have been reported (83). Symptoms and signs 
usually occur a few days following TOP and such women should be evaluated for RPOC. 
Ascending genital tract infections are caused by multiple micro-organisms and broad-
spectrum antibiotics are indicated in the management of such infections (84). 
II. Embolism 
The prevalence of fatal and non-fatal pulmonary thrombo embolism is 10 - 20 per 100 000 
abortions (85). The occurrence of amniotic fluid embolism is usually between 1 in 10 000 and 
1 in 80 000 pregnancies and when it occurs after mid-trimester abortion, it has the mortality 
rate up to 80% (86). 
2.6.3. Late complications 
I. Rhesus (RH) isoimmunisation 
RH isoimmunisation is a common late complication which can be detected in a subsequent 
pregnancy. The risk increases with an increase in gestational age and is low in association 
with abortion. One study found that 3.1% of RHD negative women were sensitized following 
suction abortion in the first trimester where Anti D immunoglobulin was not given to the 
women. In SA, the recommendation is that 50µg of Anti D be given IVI to all women who 
lose their pregnancies at less than 20 weeks (87). The RCOG recommended that all women 
who are pregnant should receive anti D after any potential sensitizing event, and this was 
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reviewed in studies looking at mid-trimester TOP using Misoprostol. Their recommendation 
after 20 weeks is to give 500 units followed by Kleinhauer test to quantify or estimate a foetal 
maternal haemorrhage so that additional Anti D can be given if required (88). 
 2.8 Aims and objectives 
The main objective of this study was to characterise women who presented to CHBAH 
between 12 and 20 weeks for termination of pregnancy between August 2012 and May 2013. 
The specific objectives were: 
 To describe women presenting to CHBAH for second trimester abortions, their 
demographics, social factors and co-morbidities  
 To determine the time to abortion and describe factors associated with an increased 
time from induction to delivery. 
 To compare sonar gestational age to gestational age by last normal menstrual period.  
 To describe the complications - amount of bleeding (including the need for 
transfusions), infection, pain, uterine rupture and perforation. 
 To describe final procedures - manual vacuum aspiration (MVA) under local 
anaesthesia, evacuation in theatre, dilation and evacuation (D & E) and hysterotomy.  
 To describe reasons for late presentation.  
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CHAPTER 3: MATERIALS AND METHODS 
This section presents the study setting and protocol of management of second trimester TOPs 
at CHBAH. The study population, sampling, study design and statistical methods are 
described. Ethical consideration and funding are outlined at the end of the chapter. 
3.1. Study setting 
The study was conducted at CHBAH, a tertiary institution that sees women mainly from 
Soweto. The population is predominantly Black but also comprises other population groups - 
Coloured, White, and Asian.  The population size of women is 640 588 which makes 50.38% 
of the adult population in Soweto (89). 
 Women requesting a TOP in the second trimester and those with medical or surgical 
complications are referred from Community Health Centres to the Gynaecology Department 
at CHBAH.  
 The unit performs between 16 and 20 second trimesters abortions per week.  The protocol 
for the management of second trimester abortion is as follows:  
Day 1: 
 Women are admitted. A complete examination and an ultrasound examination (for 
gestational age) is performed. 
 Blood tests including haemoglobin (HB), urea and electrolytes, Rhesus blood group, 
Human Immunodeficiency Virus (HIV) testing and other tests that are clinically necessary 
are done.  
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 The woman is given 600 µg of Misoprostol to be administered vaginally at about 22H00, 6 
hourly for 3 doses. Or until she has pain or bleeding. 
 If there is pain and bleeding, an Oxytocin IVI of 20 milliunits /min is started. If she fails to 
abort, she proceeds to the next day’s regimen. 
Day 2: 
 The doctor inserts 800 µg Misoprostol into the posterior fornix at 08H00.  
 This is followed 3 hours later by 20 units of IV Oxytocin in 1 litre normal saline to run at 
125ml per hour.  
 If she fails to abort, she proceeds to day 3 regimens. 
Day 3: 
 PG E2 (prepidil gel) 0.5mg is administered  intracervically 
 OR two doses of Misoprostol at 400 µg are given vaginally 6 hourly followed by Oxytocin 
IVI 20 units in 1 litre of normal saline 3 hours later.  
 OR an extra amniotic infusion of PG F2ἀ 5mg in 200ml normal saline over 5 hours.  If she 
fails to abort, this constitutes a failed medical termination which necessitates other 
methods of abortion on day 4. 
Day 4: 
 The procedure to be done is dependent on the surgeon and this could be a hysterotomy, 
D&E or suction curettage. 
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In those women where there is an incomplete abortion, an MVA under analgesia or under 
anaesthesia or an evacuation in theatre is performed. The choice of procedure is dependent on 
the surgeon and individualised on the clinical findings.  Patients are generally discharged 2- 6 
hours after a procedure. Contraceptive choices are discussed. Discharge after a hysterotomy 
occurs 48 - 72 hours in uncomplicated cases.  
3.2. Study design, study population and sampling 
A prospective cohort study of women who presented at CHBAH for second trimester 
termination of pregnancy between August 2012 and May 2013 was performed. The study 
sample was a convenience sample where women were recruited 3 days a week. All women 
aged 18 and above and of between 13 and 20 weeks of gestation were included in the study. 
The exclusion criterion was as follows: 
 Pregnancy more advanced than 20 weeks gestation.  
 Threatened miscarriage at any gestation.  
 Women requiring TOP due to severe pre eclampsia, eclampsia or other medical 
disease. 
 Women unwilling or unable to give consent. 
 Women whose TOPs were started outside the institution. 
3.3. Data collection 
The data was collected from medical files and by interviewing women on day 1 and again on 
discharge (Data sheet and questionnaire – Appendix A). The researcher returned every 
afternoon and morning to assess the progress of women who had been recruited, but only 
recruited 3 days a week. 
Baseline and explanatory variables recorded from patients file and by interview include: 
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 Demographics: highest level of education achieved, home language, marital status, 
monthly income, age, HIV status, smoking, alcohol, drug use and contraception use. 
 Date and time of admission, date and time of Misoprostol insertion.  
 Gestational age, Bishops score, HB done on admission, previous obstetrics history. 
 Reasons to terminate the pregnancy and for not having the TOP in the first trimester 
of pregnancy. 
Outcome variables included the following: 
 Date and time of abortion  
 Bleeding,  
 The need for blood transfusion, 
  Pain,  
 Infection and 
 Other complications and surgical procedures. 
Blood loss was quantified by using a 10 point scale where women were asked to grade 
bleeding they sustained during the course of TOP from 0-10. Bleeding from 6 and above was 
considered severe. Using the visual assessment score (VAS) scale bleeding of more than 6 
was considered severe. 
Pain was also quantified by using a 10 point scale where women were asked to grade the pain 
they sustained during the course of the TOP. Pain was graded from 0-10 with the score of 6 
and above considered a severe pain. 
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3.4. Data processing and analysis 
All data collected was captured into a Microsoft Excel spreadsheet 2007 and exported to 
STATA 10 statistical software (Stata Corp, Texas, and USA) for analysis. The data was 
explored and all outliers were re-checked with the source data (Medical files). All categorical 
variables were described using frequencies and percentages and continuous variables were 
described using means with standard deviations and medians. Ranges were also presented. 
Those women who did not abort the foetus were coded as “0” and those who aborted the 
foetus were coded as “1”, even if the abortion was incomplete. Those who did not abort were 
excluded from the time to abort analysis.  
All the explanatory variables were compared in those individuals who aborted and in those 
who did not abort. The cross tabulation tables were performed with every explanatory 
variable and the outcome. For the numeric (continuous) variables – the Wilcoxon rank sum 
test was used to test the equality of the median values where the variables were not normally 
distributed. Normality was assessed both graphically (using box and whisker plots and 
histogram plots) and statistically (using the Shapiro-Wilk test). For normally distributed 
numeric variables the t-test was used. All categorical variables were compared using the Chi2 
test or the Fisher exact test for those that had fewer than 5 observations in a cell. 
A new variable: “Time to abortion” was made which was the outcome of interest. The Kaplan 
- Meier curve was drawn to show incidence of abortion in those who had aborted. 
3.5. Ethics 
The study was approved by the Human Research Ethics Committee (HREC) of the 
University of the Witwatersrand. The approval letter with clearance number: M120653 is 
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attached below as Appendix C. Hospital permission to conduct the study was granted by the 
CHBAH Medical Advisory Committee on behalf of the CEO as noted in Appendix D. All 
participants provided written informed consents (Appendix B). Confidentiality and 
anonymity were ensured by not using women’s names and addresses or birth dates on the 
data sheet and questionnaire. 
Study procedures were carried out in accordance with the revised version of the Helsinki 
Declaration and with the standards of good clinical practice.  The women were all given an 
information sheet and the details and procedures were then fully explained to them. Time was 
given to ask questions. The consent form, Appendix B, was signed by those willing to 
participate in the study prior to commencing with data collection. A separate list of recruited 
women was kept with names and hospital numbers because women had to be followed up 
until discharge and for record purposes. 
3.6. Funding 
Funds were only needed for stationery, files and printing.  Photocopying and funding was 
borne by a researcher. 
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CHAPTER 4: RESULTS 
4.1. Introduction 
In this chapter, results are presented by first describing the study population. Outcomes, 
complications, reasons why women requested an abortion and reasons for the request in the 
second trimester are then described.  
4.2. Women eligible for interview 
The total number of women who were included in the study was 211 as described in figure 1 
below. There were 338 women between 12 weeks and 20weeks pregnant that were admitted 
between 14 August 2012 and 13 May 2013 and 21 were under 12 weeks pregnant. 
                  382 women admitted for TOP                
                  382 ↓→ 21 women had first trimester TOP 
                  361 ↓ → 23 Women were less than 18 years of age 
                  338 ↓ →127 women were not interviewed  
                  211 Women were included in the study 
Fig 1: A schematic representation showing the number of women eligible for interview.                
Women were ethnically diverse. The largest proportion of women were Zulu speaking 65 
(30.80%) and only 2 (0.95%) spoke Ndebele. Their ethnicity, highest education attained and 
marital status and are summarised in table 1 below. 
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Table 1: A list of women’s Ethnicity, education and marital status 
  N (%) 
Ethnicity 
 Zulu 65 30.80%) 
 Southern Sotho 43 (20.38%) 
 Xhosa 31 (14.69%) 
 Tswana 19 (9.00%) 
 Pedi 11 (5.21%) 
 Tsonga 10 (4.74%) 
 Zimbabwean languages 7 (3.32%) 
 Venda 4 (1.89%) 
 Ndebele 2 (0.95%) 
 Other 19 (9.00%) 
Education 
 No  education 5 (2.37%) 
 Primary education 155 (73.46%) 
 Secondary education 50 (23.70%) 
 Tertiary education 1 (0.47%) 
Marital status 
 Not living with partner 95 (45.02%) 
 Living with partner 26 (12.32%) 
 Married 12 (5.69%) 
 Single (no partner) 74 (35.07%) 
 Widowed 3 (1.42%) 
 Divorced 1 (0.47%) 
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Most women had an income of less than R3000. 00 per month as shown in the figure 2 
below. 
 
Fig 2: A description of the income per month. 
The mean age of women was 26.52 (SD± 6.38), the median age was 25 (IQR- 21-31) and the 
range was 18 - 43. Thirty (14.22%) women smoked cigarettes, 60 (28.44%) used alcohol and 
none of them admitted to using recreational drugs. The mean parity of the women was 1.63 
(SD± 1.34).  The median was 1 with the IQR 1-2 and a range of 0 - 6.  The previous 
obstetrics history was that most women had had a normal vaginal delivery (NVD), n=146 
(69.19%), 35 (16.67%) had a caesarean section and 4 (1.89%) had had a previous TOP. 
One hundred and three women (48.81%) were using contraception at the time of conception. 
Ten (4.74%) - of these said that the method had been used correctly.  Condom failures were 
reported as the highest. 
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Ninety three women gave possible reasons for contraception failure and explained the failures 
as follows; 34 (38.64%) had condom accidents; 31 (35.23%) had missed their pill; 4(4.54%) 
used combined oral contraception (COC) with antibiotics; 21 (23.86%) missed their injection 
and 3 (1.42%) had a delay in the time that they had to take injection. 
Fifty one (24.17%) women were found to be HIV positive and the HIV status of 14 (6.64%) 
women was unknown. The mean CD4 cell count was 468.54 (SD±200.31).The median was 
500 (IQR=350-560). The range was 45 - 913. Twenty three women (48.94%) of those who 
were HIV positive used antiretroviral therapy (ART). 
4.3. Complications 
Ninety- nine women (46.92%) bled severely. The mean blood loss using the VAS was 5.86 
(SD±1.45). The median was 6.00 with the IQR = 5-7 and the range were 2 - 9. 
There were 187 women (88.62%) whose Hb was known on admission, of those the mean Hb 
was 12.12 (SD ± 1.32). The median was 12.3 with the IQR of 11.4 -13. The range was 6.9-
15.5. The Hb was only repeated if it was clinically indicated. Sixteen women (7.58%) needed 
their HB measured after the procedure and 7 (43.75%) of the 16 needed blood transfusions. 
The mean Hb (n=16) was 8.82 (SD± 2.20) and the median of 8.55 with the IQR 7.00-10.90. 
The range was 5.60-12.60.     
 Almost all 210 women (99.52%) felt pain during the course of TOP process. One hundred 
and twenty two women (57.82%) needed analgesia for pain and 89 (42.18%) received and 
used it. The mean pain according to the VAS was 6.14 (SD±1.74). The median was 6 with 
the IQR=5-7 and the range was 2-10. 
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Antibiotics were prescribed for 192 women (91.43%) during the TOP procedure. There were 
28 women (13.27%) who had temperature spikes above 37.5 degree Celsius. One woman 
(0.47%) sustained uterine perforation after evacuation of the uterus in theatre and another 
woman (0.47%) had persistent hyperkaleamia post MVA. 
4.4. Reasons for TOP 
Table 2 shows that the main reason for requesting TOP was financial problems, followed by 
education and relationship problems. Women with relationship problems included those 
whose partners were cheating and abusive, while other women wanted to further their studies. 
Those with “family influence” were where parents influenced their decision.    
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Table 2:  A list of the reasons for requesting TOP 
Reasons for requesting a 
TOP 
Number of women 
n=211(%) 
Financial problems 61 (28.91%) 
Education 35 (16.58%) 
Relationship problems 34 (16.11%) 
Baby still young 17 (8.06%) 
Family completeness 16 (7.58%) 
Not ready to be a mother 13 (6.16%) 
HIV status 9 (4.26%) 
No reason given 9 (4.26%) 
Raped 6 (2.84%) 
Family influence 4 (1.89%) 
Medical reasons 4 (1.89%) 
Incarceration in jail 1 (0.47%) 
4.5. Reasons for coming late for TOP 
Table 3 shows reasons for not having the TOP in the first trimester. Thirty one women 
(14.69%) experienced logistic and staff related problems at the clinic with their first 
consultation. Some women, 6 (2.84%) lacked information about where and how to seek TOP 
while 3 women (1.42%) had relationship problems like partner not supportive of pregnancy 
and partner vanishing. 
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Table 3: A list of the reasons for coming late for TOP 
Reasons Number of women n=211(%) 
Pregnancy diagnosed late 92 (43.60%) 
The decision was taken late 39 (18.48%) 
Clinic related problems 31 (14.69%) 
Underestimated gestational age 15 (7.11%) 
Was scared and confused 9 (4.26%) 
Information on how to get abortion 7 (2.37%) 
Work related constraints 6 (2.84%) 
Financial constraints 4 (1.89%) 
Relationship problems 4 (1.89%) 
Exam/education 2 (0.95%) 
Others 2(0.95%) 
4.6. Gestational age 
There was a poor correlation between dates calculated using the woman’s dates and those 
calculated using ultrasound dating with a Spearman’s rho of 0.38(p=0.00). The table below 
gives the values and the graph shows the differences with using the two methods of 
gestational age calculation. 
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 Table 4: A comparison of gestational age calculated using dates (LNMP) and 
Ultrasound. 
Modality used 
to calculate 
gestational age 
 
Gestational age in weeks 
 
 
Mean  
(SD) 
Median (IQR) Range 
 
Sonar 
15.18 
(±1.67) 
14.71 
(13.86- 16.14) 
13.00-20.00 
 
Dates  
13.77 
(±2.69) 
13.57 
(12.28-15.00) 
4.14-26.28 
 
 
Figure 3: A box and whisker plot comparing sonar gestational age to gestational age by 
dates. The correlation between dates and sonar is median of 1 week. 
      Days 
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4.7. Final procedures 
One hundred and thirty five women (63.98%) had an MVA using analgesia.  The number of 
women who had an evacuation in theatre was 39 (18.48%) and 14 women (6.63%) needed 
suction curettage in theatre under general anaesthesia. Two women (0.95%) needed a 
hysterotomy, another 2 women (0.95%) required D&E in theatre. Nineteen women (9.00%) 
aborted both foetus and placenta completely and did not need any further intervention. 
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Table 5: Comparison between women who aborted and those that did not after 72 
hours. 
 Aborted n= 191    
(91.39%) 
Failed to abort after 
72 hours- 18(8.61%) 
P value 
Age 26.03 (SD±6.25) 31.67(SD±5.81) 0.00 (Chi2) 
Less than and equal 
to 25years 
102 (53.40%) 3 (16.67%) 0.00 (FE) 
Greater than 25years 89 (46.60%) 15 (83.33%) 
 
 
Parity 1.59(SD±1.34) 2.00(SD±1.46) 0.27t-test 
Type of delivery if the patient had had a prior delivery 
 
C/S n=35 31 (20.13%) 4 (25.00%) 0.74 (FE) 
NVD n=135 123 (79.87%) 12 (75.00%) 
Gestational age 
 
Gestational age-
mean(weeks) 
13.77(2.76) 13.52 (1.81) 0.60 (t-test) 
Gestational age on 
sonar>14 weeks 
140(73.30%) 8(44.44%) 0.01 Chi2 
HIV 
 
HIV positive 44 (24.86%) 7 (38.89%) 0.20 (Chi2) 
HIV negative 133 (75.14%) 11 (61.11%) 
Social factors 
 
Alcohol use  54 (28.27%) 5 (27.78%) P=1.00(FE) 
Smoking 25 (13.09%) 4 (22.22%) P=0.29 
Haemoglobin 
 
Hb less than 10.5 18 (9.42%) 3 (16.67%) 0.33 
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Women who were older than 25 years were 33% less likely to abort than women less than    
25 years. 
4.8. Time to abortion 
The mean time to abortion was 15.61 hours (SD±18.80). Median was 11.50 hours with 
IQR=8.67-17.92 and the range was 3.50 - 69.33.The incidence rate was 0.5 per hour or 1 per 
2hours. This time was calculated from the time the first Misoprostol was inserted to the time 
of the abortion of the foetus.  
Figure 4: Kaplan- Meier survival curve showing the incidence of abortion 
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CHAPTER 5: DISCUSSION  
The study is the first in recent years at CHBAH to prospectively characterise women coming 
for TOP in the second trimester.  
One of the major finding was that 191women (91.39%) aborted following a medical 
induction using Misoprostol only. MVA and evacuation were done to complete a medical 
induction after assessment by clinicians. There were few women who aborted completely 
following medical induction. The assessment of whether an abortion was complete or not was 
made between 1 and 8 hours after the abortion. It may be that many of these women would 
have had a complete abortion if the time for the assessment was longer.  South Africa also 
has had a recent history of having had stringent abortion laws making the association between 
septic incomplete abortion and maternal morbidity and mortality  a major concern, this may 
also contribute to the larger number of women who had to have an MVA.   
The study’s main outcome underlines the efficacy of Misoprostol as the first line drug for 
second trimester TOP in this setting. The failure rate of the drug was 9.48% and is 
comparable with other local studies. Gamedze reported 5% while Basu reported 8 %( 67). 
In terms of the demographics and characteristics of the sampled population, the majority of 
women 45% were Nguni (Zulu and Xhosa speaking) with little education, poor financial 
background and a poor marital support system which appeared to have played a bigger role in 
the decision to terminate the pregnancy.  
Their mean age was 26.52 ±6.38 (18 - 43) which is comparable to local and international 
studies. Internationally, Ngoc et al (90) reported a mean age of 25±6.8 (15-49) in a study to 
estimate the clinical benefit of pre - treatment with Mifepristone followed by Misoprostol 
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compared with Misoprostol alone for second trimester TOP. Locally, studies by Gamedze 
and Basu et al (69) showed similar mean ages of 25.90 (SD) and 25.00 (SD). It is of concern 
that there were 103 women who were using contraception and that these methods failed. It is 
important that when educating women on contraception, possibilities of methods failure be 
discussed in combination with advice on emergency contraception.  
 Sixteen women (7.58%) needed their HB re - measured after the procedure and 7(43.75%) of 
16 needed blood transfusion. The mean HB was 8.82±2.20, higher than in other studies on 
second trimester abortion and is higher than other studies both local and international studies 
which reported mean HB as low as 1±0.6 in a study by Shaw et al (94) n=158. 
In this study antibiotics were used liberally prescribed and were used for 192 women 
(91.43%). Twenty eight women (13.27%) had temperature spikes above 37.5 degrees Celcius 
warranting an extended period on IVI antibiotics.  
There was however no serious morbidity requiring intensive care unit i.e. DIC and no death 
occurred during the study period.  
One uterine perforation was reported during evacuation using sharp curettage. Most of the 
procedures were done using suction rather than sharp curettage and that may have also 
contributed to the low rate of perforation. This may also be that the majority of health care 
providers are well trained to carry out the evacuation of the uterus. Shaw et al (94), reported 2 
perforations (1.26%), n=158 sample was small.  
The majority of women 92(43.60%) reported not being aware of pregnancy as their main 
reason for presenting late for pregnancy termination. Some women 31(14.69%) reported poor 
referral system as main reason for a delay.  
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There was poor correlation between assessment of gestational age by dates and by sonar. The 
mean gestational age by ultrasound was 15.8±1.67 (13.00-20.00) and mean gestational age by 
date was 13.77±2.69 (4.14-26.28) .However, the median of 1 week was found and clinically 
this is in fact a very good correlation. Ultrasound and dates are not expected to agree 
completely in value. Reason for this difference could be due to women’s failure to remember 
their last normal menstrual period. This population of women may be different from women 
who are planning a pregnancy and who would therefore easily remember their menstrual 
dates.  
Two women (0.95%) needed hysterotomy to complete TOP. This finding was comparable 
with other local studies. Basu et al (69) reported (0.53%). Two women (0.95%) needed 
dilation and evacuation to complete TOP. Fourteen women (6.63%) needed suction curettage 
in theatre to complete TOP under general anaesthesia which is incomparable to other local 
studies. 
In comparing characteristics of women who aborted  and failed to abort after 72 hours it was 
noted that women less than and equal to 25 years aborted quicker than women greater than 25 
years despite their higher parity.  
The history of having had a caesarean section was not significantly different in this study. 
Thirty one women (88.57%) with prior caesarean section aborted while 4 (11%) failed to 
abort which is comparable with other local studies. Basu (69) reported 42(89%) for the 
abortion group and 5(11%) for the failure group, n=47.This outcome is however not 
important for our study. 
The mean time to abortion was 15.61hours±18.80 (3.50-69.33) hours. This time was 
calculated from the time of the first Misoprostol insertion to the time of abortion. This is 
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similar to local studies which reported 16.7 hours (69). The findings were not comparable 
with an international study by Ngoc et al (90) which reported 10.6hours±2.5 (6.5-15.5) hours. 
This may be because they were using the Misoprostol dosage of 400µg 3 hourly which 
maintains high concentration of Misoprostol and facilitates a quicker abortion compared to 
the protocol of vaginal Misoprostol 600µg 6 hourly. The RCOG recommends 400µg of 
vaginal Misoprostol 3 hourly for up to 5 dosages in termination of pregnancy between 13 and 
22 gestational weeks (91). More frequent doses decrease the abortion time interval. Two 
meta-analyses reported significantly shorter induction to abortion time with 3 hourly vaginal 
administration of 400µg of Misoprostol than 6 hourly dosages without a significant rise in 
side effects (92). In the current study, giving a higher dose of 600µg 6 hourly achieved higher 
success rate and this worked better for the unit in view of the shortage of mid wives required 
to manage these abortions. 
6 Strengths 
The study was conducted at CHBAH located in Soweto, serving a greater part of southern 
Gauteng. These women are similar to women who attend public health facilities in other parts 
of the country and therefore these findings may be generalizing. The researcher speaks 8 
languages and carried out all the interviews.  
7 Limitations 
 There was no uniformity in the recording of history and examination findings in the patient’s 
files. Variables like time of admission, bishop score and times of discharge were often not 
complete. This was a convenience sample and rare outcomes or complication might have 
been missed but we also may have overestimated some complications. Lack of follow up of 
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patients after discharge may lead to patients presenting elsewhere and this may lead to 
inability to capture delayed complications. 
Measurement of some outcomes like blood loss and pain will be difficult since individual 
women may understand grading differently and grade them differently.  
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8 Conclusion and Recommendations 
The findings show that most women, n= 191 (91.39%) aborted the foetus with the use of 
Misoprostol only. While the number of women who abort in the first 24 hours is acceptable, 
there is still some percentage of women who will remain in the hospital for a longer period. 
Eighteen (8.61%) women who did not abort in 72 hours required a surgical TOP. The number 
of women requiring an MVA was high, but this may be because repeat Misoprostol would 
mean a longer hospital stay. 
 Even though the WHO and other abortion bodies worldwide still favour D&E for second 
trimester TOP,  in this hospital Misoprostol and evacuation of RPOC have shown that 
reasonable success. It may be that clinicians in this service are not trained to perform D&E. 
Studies perfomed have shown that clinicians are not comfortable conducting D&E because of 
lack of training and experience and the fact that it is psychologically traumatic (93).  
 Proper contraception services and sexual education will help prevent unwanted pregnancies 
amongst the young and old. Pregnancy tests should be available at primary health care 
services. Education regarding early signs and symptoms of pregnancy and adequate first 
trimester abortion will help reduce incidences of second trimester abortions. 
Our protocols need to consider adding Mifepristone to decrease the time to abortion and 
using ultrasound post abortion to assess the completeness of the medical procedure. Future 
research is necessary to look at the high MVA rate after abortion of the foetus and whether 
repeat Misoprostol in such situations could reduce the risk of RPOC. 
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